|
1
|
European Association For The Study Of The
Liver and European Organisation For Research And Treatment Of
Cancer. EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Greten TF, Wang XW and Korangy F: Current
concepts of immune based treatments for patients with HCC: From
basic science to novel treatment approaches. Gut. 64:842–848.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Yan W, Liu X, Ma H, Zhang H, Song X, Gao
L, Liang X and Ma C: Tim-3 fosters HCC development by enhancing
TGF-β-mediated alternative activation of macrophages. Gut.
64:1593–1604. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sarin SK, Kumar M, Eslam M, George J, Al
Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, et al:
Liver diseases in the Asia-Pacific region: A lancet
gastroenterology & hepatology commission. Lancet Gastroenterol
Hepatol. 5:167–228. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shiha G, Sarin SK, Ibrahim AE, Omata M,
Kumar A, Lesmana LA, Leung N, Tozun N, Hamid S, Jafri W, et al:
Liver fibrosis: Consensus recommendations of the Asian Pacific
association for the study of the liver (APASL). Hepatol Int.
3:323–333. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tewari D, Patni P and Bishayee A, Sah AN
and Bishayee A: Natural products targeting the PI3K-Akt-mTOR
signaling pathway in cancer: A novel therapeutic strategy. Semin
Cancer Biol. 80:1–17. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kim DH, Yoon JH, Choi MH, Lee CH, Kang TW,
Kim HA, Ku YM, Lee JM, Kim SH, Kim KA, et al: Comparison of
non-contrast abbreviated MRI and ultrasound as surveillance
modalities for HCC. J Hepatol. 81:461–470. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang Z, Qin H, Liu S, Sheng J and Zhang X:
Precision diagnosis of hepatocellular carcinoma. Chin Med J (Engl).
136:1155–1165. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ringelhan M, Pfister D, O'Connor T,
Pikarsky E and Heikenwalder M: The immunology of hepatocellular
carcinoma. Nat Immunol. 19:222–232. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Elsegood CL, Tirnitz-Parker JE, Olynyk JK
and Yeoh GC: Immune checkpoint inhibition: Prospects for prevention
and therapy of hepatocellular carcinoma. Clin Transl Immunology.
6(e161)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shrestha R, Prithviraj P, Anaka M, Bridle
KR, Crawford DHG, Dhungel B, Steel JC and Jayachandran A:
Monitoring immune checkpoint regulators as predictive biomarkers in
hepatocellular carcinoma. Front Oncol. 8(269)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yun J, Yu G, Hu P, Chao Y, Li X, Chen X,
Wei Q and Wang J: PD-1 expression is elevated in monocytes from
hepatocellular carcinoma patients and contributes to CD8 T cell
suppression. Immunol Res. 68:436–444. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang Q, Sun P, Huang H, Zhang Q, Sun X,
Wang Z and Pu C: GPC3 in liver cancer exosomes: Dual regulation of
growth in normal and hepatocellular carcinoma cells through the
Wnt/β-catenin signaling pathway. Bull Biomed Sci. 1:67–76.
2023.
|
|
15
|
Liaw YF and Chu CM: Hepatitis B virus
infection. Lancet. 373:582–592. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lavanchy D: Worldwide epidemiology of HBV
infection, disease burden, and vaccine prevention. J Clin Virol. 34
(Suppl 1):S1–S3. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yin J, Xie J, Liu S, Zhang H, Han L, Lu W,
Shen Q, Xu G, Dong H, Shen J, et al: Association between the
various mutations in viral core promoter region to different stages
of hepatitis B, ranging of asymptomatic carrier state to
hepatocellular carcinoma. Am J Gastroenterol. 106:81–92.
2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li P, Du Q, Cao Z, Guo Z, Evankovich J,
Yan W, Chang Y, Shao L, Stolz DB, Tsung A and Geller DA:
Interferon-γ induces autophagy with growth inhibition and cell
death in human hepatocellular carcinoma (HCC) cells through
interferon-regulatory factor-1 (IRF-1). Cancer Lett. 314:213–222.
2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li J, Zeng M, Yan K, Yang Y, Li H and Xu
X: IL-17 promotes hepatocellular carcinoma through inhibiting
apoptosis induced by IFN-γ. Biochem Biophys Res Commun.
522:525–531. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yu X, Lang B, Chen X, Tian Y, Qian S,
Zhang Z, Fu Y, Xu J, Han X, Ding H and Jiang Y: The inhibitory
receptor Tim-3 fails to suppress IFN-γ production via the NFAT
pathway in NK-cell, unlike that in CD4+ T cells. BMC
Immunol. 22(25)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wu Y, Min J, Ge C, Shu J, Tian D, Yuan Y
and Zhou D: Interleukin 22 in liver injury, inflammation and
cancer. Int J Biol Sci. 16:2405–2413. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shabgah AG, Navashenaq JG, Shabgah OG,
Mohammadi H and Sahebkar A: Interleukin-22 in human inflammatory
diseases and viral infections. Autoimmun Rev. 16:1209–1218.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Saalim M, Resham S, Manzoor S, Ahmad H,
Bangash TA, Latif A and Jaleel S: IL-22 in hepatocyte's survival of
Pakistani patients with end stage liver disease: An insight into IL
22 mediated hepato-regenerative pathway. Mol Biol Rep.
46:1127–1138. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Saalim M, Resham S, Manzoor S, Ahmad H,
Jaleel S, Ashraf J, Imran M and Naseem S: IL-22: A promising
candidate to inhibit viral-induced liver disease progression and
hepatocellular carcinoma. Tumour Biol. 37:105–114. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lu Y, Wu Z, Peng Q, Ma L, Zhang X, Zhao J,
Qin X and Li S: Role of IL-4 gene polymorphisms in HBV-related
hepatocellular carcinoma in a Chinese population. PLoS One.
9(e110061)2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wan J, Wu Y, Ji X, Huang L, Cai W, Su Z,
Wang S and Xu H: IL-9 and IL-9-producing cells in tumor immunity.
Cell Commun Signal. 18(50)2020.PubMed/NCBI View Article : Google Scholar
|
